References
- Ugurel S, Rohmel J, Ascierto PA, et al. Survival of patients with advanced metastatic melanoma: the impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. Eur J Cancer (Oxford, England: 1990). 2020;May 130 126–138.
- Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 Nov;19(11):1480–1492.
- Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019 Sep;20(9):1239–1251.
- Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022 Jan 6;386(1):24–34.
- Michielin O, van Akkooi ACJ, Ascierto PA, et al. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger. Ann Oncol. 2019 Dec 1;30(12):1884–1901.
- Reddy BY, Miller DM, Tsao H. Somatic driver mutations in melanoma. Cancer. 2017 Jun 1;123(S11):2104–2117.
- Ascierto PA, Kirkwood JM, Grob JJ, et al. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012 Jul 9;10(1):85.
- Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012 Nov 1;367(18):1694–1703.
- Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019 Aug 15;381(7):626–636.
- Ascierto PA, McArthur GA, Dreno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016 Sep;17(9):1248–1260.
- Ascierto PA, Dummer R, Gogas HJ, et al. Update on tolerability and overall survival in Columbus: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Eur J Cancer (Oxford, England: 1990). 2020;Feb 126 33–44.
- SERVICES USDOHAH. Common terminology criteria for adverse events (CTCAE) 2017. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdf
- Regnier-Rosencher E, Lazareth H, Gressier L, et al. Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas. Br J Dermatol. 2013 Oct;169(4):934–938.
- Jhaveri KD, Sakhiya V, Fishbane S. Nephrotoxicity of the BRAF inhibitors vemurafenib and dabrafenib. JAMA Oncol. 2015 Nov;1(8):1133–1134.
- Wanchoo R, Jhaveri KD, Deray G, et al. Renal effects of BRAF inhibitors: a systematic review by the cancer and the kidney international network. Clin Kidney J. 2016 Apr;9(2):245–251.
- Jansen YJ, Janssens P, Hoorens A, et al. Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib. Melanoma Res. 2015 Dec;25(6):550–554.
- Seethapathy H, Lee MD, Strohbehn IA, et al. Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib. Nephrol Dialysis Trans. 2022 Feb 25;37(3):507–514.
- Krelle A, Mathai VK, Kirkland G, et al. Acute granulomatous interstitial nephritis in a patient with metastatic melanoma on targeted therapy with dabrafenib and trametinib-A case report. Cancer rep (Hoboken, NJ). 2021 Aug 5;5(7):e1520.
- Daud A, Tsai K. Management of treatment-related adverse events with agents targeting the MAPK pathway in patients with metastatic melanoma. Oncologist. 2017 Jul;22(7):823–833.
- Dreno B, Ascierto PA, McArthur GA, et al. Adverse event (AE) incidence rates with cobimetinib (C) plus vemurafenib (V) treatment: extended follow-up (f/u) of the phase III coBRIM study. J Clin Oncol. 2016 May 20;34(15):9533.
- Grob JJ, Flaherty K, Long GV, et al. Pooled analysis of safety over time and link between adverse events and efficacy across combination dabrafenib and trametinib (D plus T) registration trials. J Clin Oncol. 2016 May 20;34(15):9534.
- Heinzerling L, Eigentler TK, Fluck M, et al. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO open. 2019;4(3):e000491.
- Meirson T, Asher N, Bomze D, et al. Safety of BRAF+MEK inhibitor combinations: severe adverse event evaluation. Cancers (Basel). 2020 Jun 22;12(6):1650.
- Grogan N, Swami U, Bossler AD, et al. Toxicities with targeted therapies after immunotherapy in metastatic melanoma. Melanoma Res. 2018 Dec;28(6):600–604.
- Seethapathy H, Bates H, Chute DF, et al. Acute kidney injury following encorafenib and binimetinib for metastatic melanoma. Kidney med. 2020 May-Jun;2(3):373–375.
- Wanchoo R, Devoe C, Jhaveri KD. BRAF inhibitors - do we need to worry about kidney injury? Expert Opin Drug Saf. 2016 May;15(5):579–581.
- Launay-Vacher V, Zimner-Rapuch S, Poulalhon N, et al. Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients. Cancer. 2014 Jul 15;120(14):2158–2163.
- Maanaoui M, Saint-Jacques C, Gnemmi V, et al. Glomerulonephritis and granulomatous vasculitis in kidney as a complication of the use of BRAF and MEK inhibitors in the treatment of metastatic melanoma: a case report. Medicine (Baltimore). 2017 Jun;96(25):e7196.
- Teuma C, Perier-Muzet M, Pelletier S, et al. New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma. Cancer Chemother Pharmacol. 2016 Aug;78(2):419–426.
- European Medicines Agency. Tafinlar. annex 1: summary of product characteristics 2013 [updated 2021 Dec 09]. Available from: https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf
- European Medicines Agency. Zelboraf. annex 1: summary of product characteristics 2012 [updated 2021 Nov 24]. Available from: https://www.ema.europa.eu/en/documents/product-information/zelboraf-epar-product-information_en.pdf
- European Medicines Agency. Braftovi. annex 1: summary of product characteristics 2018 [updated 2022 Jan 28]. Available from: https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf
- Chaib H, Hoskins BE, Ashraf S, et al. Identification of BRAF as a new interactor of PLCepsilon1, the protein mutated in nephrotic syndrome type 3. Am J Physiol Renal Physiol. 2008 Jan;294(1):F93–9.
- Hurabielle C, Pillebout E, Stehle T, et al. Mechanisms underpinning increased plasma creatinine levels in patients receiving vemurafenib for advanced melanoma. PloS one. 2016;11(3):e0149873.
- Perico L, Mandala M, Schieppati A, et al. BRAF signaling pathway inhibition, podocyte injury, and nephrotic syndrome. Am J Kidney Dis. 2017 Jul;70(1):145–150.
- Troxell ML, Higgins JP, Kambham N. antineoplastic treatment and renal injury: an update on renal pathology due to cytotoxic and targeted therapies. Adv Anat Pathol. 2016 Sep;23(5):310–329.
- Praga M, Gonzalez E. Acute interstitial nephritis. Kidney Int. 2010 Jun;77(11):956–961.
- Fernandez-Juarez G, Perez JV, Caravaca-Fontan F, et al. Duration of treatment with corticosteroids and recovery of kidney function in acute interstitial nephritis. Clin J Am Soc Nephrol. 2018 Dec 7;13(12):1851–1858.
- Kleinknecht D. Interstitial nephritis, the nephrotic syndrome, and chronic renal failure secondary to nonsteroidal anti-inflammatory drugs. Semin Nephrol. 1995 May;15(3):228–235.
- Cortazar FB, Kibbelaar ZA, Glezerman IG, et al. Clinical features and outcomes of immune checkpoint inhibitor-associated aki: a multicenter study. J Am Soc Nephrol. 2020 Feb;31(2):435–446.
- ClinicalTrials.gov. Studies found for: dabrafenib and trametinib OR encorafenib and binimetinib OR vemurafenib and cobimetinib [updated 2022 Mar 24]. Available from: https://clinicaltrials.gov/ct2/results?cond=&term=dabrafenib+and+trametinib+OR+encorafenib+and+binimetinib+OR+vemurafenib+and+cobimetinib&cntry=&state=&city=&dist=&Search=Search&type=Intr